<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Otavio Berwanger | Biostatistician</title>
    <link>https://gasparyan.co/author/otavio-berwanger/</link>
      <atom:link href="https://gasparyan.co/author/otavio-berwanger/index.xml" rel="self" type="application/rss+xml" />
    <description>Otavio Berwanger</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><copyright>© 2022 Samvel B. Gasparyan</copyright><lastBuildDate>Mon, 26 Jul 2021 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://gasparyan.co/images/icon_hu37ae94fde7f6135a8e8cfd653ea9ade8_11929814_512x512_fill_lanczos_center_2.png</url>
      <title>Otavio Berwanger</title>
      <link>https://gasparyan.co/author/otavio-berwanger/</link>
    </image>
    
    <item>
      <title>Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19)</title>
      <link>https://gasparyan.co/publication/dare-19-primary/</link>
      <pubDate>Mon, 26 Jul 2021 00:00:00 +0000</pubDate>
      <guid>https://gasparyan.co/publication/dare-19-primary/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study</title>
      <link>https://gasparyan.co/publication/dare-19-design/</link>
      <pubDate>Tue, 15 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://gasparyan.co/publication/dare-19-design/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
